SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(D'Amico AV)
 

Sökning: WFRF:(D'Amico AV) > Variation in the de...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005652naa a2200469 4500
001oai:gup.ub.gu.se/43842
003SwePub
008240528s2007 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/438422 URI
0247 a https://doi.org/10.1016/j.juro.2006.10.0972 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Cookson, MS4 aut
2451 0a Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes
264 1b Ovid Technologies (Wolters Kluwer Health),c 2007
520 a Purpose The American Urological Association Prostate Guideline Update Panel was charged with updating the Guidelines for Clinically Localized Prostate Cancer. In assessing outcomes with treatment, it became apparent that a highly variable number of definitions exist with respect to biochemical recurrence. Herein, we review the variability in published definitions of biochemical recurrence and make recommendations directed toward improving this terminology by recommending a standard definition in patients treated with radical prostatectomy. Materials and Methods Four PubMed® literature searches were performed between May 2001 and April, 2004 and covered articles published from 1991 through early 2004. The search terms included the MeSH® major headings of prostate cancer and prostatic neoplasm. All potentially relevant articles were retrieved and a more detailed screen for relevance was performed. An article was considered relevant if it reported treatment outcomes of patients with clinical T1 or T2N0M0 prostate cancer. Data extractors recorded the definition of biochemical recurrence and definitions were then collapsed into categories representing the same criteria. The results of biochemical failure were subcategorized by initial treatment. Results Of 13,800 citations, a total of 436 articles were selected. Among these, a total of 145 articles contained 53 different definitions of biochemical recurrence for those treated with radical prostatectomy. Of these, the most common definition (35) was a prostate specific antigen of >0.2 ng/mL or a slight variation thereof. In addition, a total of 208 articles reported 99 different definitions of biochemical failure among those treated with radiation therapy. Of these, the American Society for Therapeutic Radiology and Oncology definition (70) and/or a variation thereof was the most commonly reported. In total, 166 different definitions of biochemical failure were identified. Following radical prostatectomy, the Panel recommends defining biochemical recurrence as an initial serum prostate specific antigen of ≥0.2 ng/mL, with a second confirmatory level of prostate specific antigen of >0.2 ng/mL. The Panel recommends the use of the American Society for Therapeutic Radiology and Oncology criteria for patients treated with radiation therapy and acknowledges that these criteria will soon be updated although not yet published. Conclusions A high degree of variability in the definition of biochemical recurrence exists following treatment for localized prostate cancer. Strict definitions for biochemical recurrence are necessary to identify men at risk for disease progression and to allow meaningful comparisons among patients treated similarly. The Panel acknowledges the American Society for Therapeutic Radiology and Oncology criteria and future modifications thereof for those receiving radiation therapy and recommends the newly developed American Urological Association criteria for those treated with radical prostatectomy. The purpose for the establishment of this standard is for data reporting purposes and for comparison of similarly treated patients. It is not intended to represent a threshold value for which to initiate treatment. The Panel acknowledges that the clinical decision to initiate treatment will be dependent on multiple factors including patient and physician interaction rather than a specific prostate specific antigen threshold value.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a prostate; prostatic neoplasms; prostate-specific antigen; practice guidelines
7001 a Aus, Gunnar,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut
7001 a Burnett, AL4 aut
7001 a Canby-Hagino, ED4 aut
7001 a D'Amico, AV4 aut
7001 a Dmochowski, RR4 aut
7001 a Eton, DT4 aut
7001 a Forman, JD4 aut
7001 a Goldenberg, SL4 aut
7001 a Hernandez, J4 aut
7001 a Higano, CS4 aut
7001 a Kraus, SR4 aut
7001 a Moul, JW4 aut
7001 a Tangen, C4 aut
7001 a Thrasher, JB4 aut
7001 a Thompson, I4 aut
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org
7730 t J Urold : Ovid Technologies (Wolters Kluwer Health)g 177:2, s. 540-545q 177:2<540-545
7730 t Journal of Urologyd : Ovid Technologies (Wolters Kluwer Health)g 177:2, s. 540-545q 177:2<540-545x 0022-5347x 1527-3792
8564 8u https://gup.ub.gu.se/publication/43842
8564 8u https://doi.org/10.1016/j.juro.2006.10.097

Hitta via bibliotek

  • J Urol (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy